Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Cochlear implantation, children and adults. Main billing specialty: otolaryngology.
Medicare fee-for-service cochlear implants cases in the 22 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 23% on average (17 state-years, 2020–2024): small markets swing, so treat it as rough.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 14 | 436+11%/yr | +11%/yr | 0.10.8× | 28% | 770 in 2030+9.8%/yr |
| Florida | 9 | 349+4.4%/yr | +4.4%/yr | 0.21.0× | 30% | 300 in 2030−2.5%/yr |
| Texas | 9 | 288+1.6%/yr | +1.6%/yr | 0.10.8× | 13% | 330 in 2030+2.2%/yr |
| Ohio | 4 | 209+11%/yr | +11%/yr | 0.21.2× | 0% | 320 in 2030+7.6%/yr |
| Tennessee | 7 | 205+8.7%/yr | +8.7%/yr | 0.31.8× | 28% | 290 in 2030+6.2%/yr |
| North Carolina | 5 | 192+9.9%/yr | +9.9%/yr | 0.21.2× | 21% | 300 in 2030+7.5%/yr |
| Arizona | 8 | 188+10%/yr | +10%/yr | 0.31.6× | 0% | 200 in 2030+1%/yr |
| New York | 3 | 178+1.2%/yr | +1.2%/yr | 0.10.6× | 0% | 160 in 2030−1.7%/yr |
| Illinois | 4 | 174+4.9%/yr | +4.9%/yr | 0.10.8× | 0% | 140 in 2030−3.2%/yr |
| Pennsylvania | 4 | 159+3.5%/yr | +3.5%/yr | 0.10.7× | 0% | 150 in 2030−1.3%/yr |
| Colorado | 4 | 157+3.7%/yr | +3.7%/yr | 0.32.0× | 0% | 110 in 2030−5.3%/yr |
| Washington | 3 | 144+3.9%/yr | +3.9%/yr | 0.21.2× | 33% | 320 in 2030+14%/yr |
| South Carolina | 6 | 142+4.7%/yr | +4.7%/yr | 0.21.3× | 17% | 310 in 2030+14%/yr |
| Kansas | 5 | 140+40%/yr | +40%/yr | 0.32.2× | 0% | 220 in 2030+7.8%/yr |
| Minnesota | 4 | 131+1.6%/yr | +1.6%/yr | 0.31.8× | 0% | 180 in 2030+5.5%/yr |
| Massachusetts | 4 | 130+3.6%/yr | +3.6%/yr | 0.10.9× | 0% | 220 in 2030+9.5%/yr |
| Michigan | 3 | 130−0.5%/yr | −0.5%/yr | 0.21.0× | 0% | 210 in 2030+8.1%/yr |
| Missouri | 4 | 129−5.7%/yr | −5.7%/yr | 0.21.3× | 0% | 130 in 2030−0.1%/yr |
| Georgia | 4 | 121+12%/yr | +12%/yr | 0.10.9× | 0% | 230 in 2030+11%/yr |
| Maryland | 4 | 116+2.8%/yr | +2.8%/yr | 0.10.8× | 0% | 100 in 2030−2.1%/yr |
| Indiana | 3 | 115+1.3%/yr | +1.3%/yr | 0.21.0× | 38% | 100 in 2030−1.9%/yr |
| Virginia | 3 | 115+6.7%/yr | +6.7%/yr | 0.10.7× | 0% | 150 in 2030+4.4%/yr |
Professional codes (what the surgeon bills): CPT 69930.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 220 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 4 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Cochlear | 107 |
| Advanced Bionics | 55 |
| Med-El | 44 |
| Oticon Medical | 14 |
Product codes: MCM (implant, cochlear). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
Across the covered states the share outside the hospital has moved +3 pts since 2019, to 12%.
The 10 busiest do 79% of the cases CMS names in California; 11 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Sinus surgery & balloon dilation | 1,305 | 139,655−2.1%/yr | −2.1%/yr | 173,800 in 2030+3.7%/yr |
| Ear tubes & middle ear surgery | 69 | 8,303−6.6%/yr | −6.6%/yr | 8,360 in 2030+0.1%/yr |
| Sleep apnea & airway implants | 151 | 5,383+26%/yr | +26%/yr | 5,940 in 2030+1.6%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 12 companies reported engagement with surgeons in the covered states worth $984K in consulting, speaking, meals and travel tied to these products, about $8,633 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 15 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.